MASS - 908 Devices Inc.
908 Devices (MASS) delivered strong Q1 results, raising full-year revenue guidance after a strategic acquisition in narcotics detection. Adjusted gross margins improved nearly three percentage points to 57%, and operating cash flow turned positive. The company has a solid balance sheet with nearly $100 million in cash post-acquisition and is debt free, while trading at a reasonable valuation.
908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript
908 Devices Inc. (MASS) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.
BURLINGTON, Mass.--(BUSINESS WIRE)-- #ChemicalID--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strate.
BURLINGTON, Mass.--(BUSINESS WIRE)-- #LawEnforcement--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcot.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” sect.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Mr.
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) (FSE: R74) ("Masivo" or the "Company") is pleased to provide an update on its Phase I diamond drilling program at the Cerro Colorado Project in Sonora, Mexico. The Company reports that Hole CC-26-001 has been successfully completed and extended beyond its original planned depth, intersecting a significant interval of what looks to be visible mineralization that is hosted within thick quartz veinlets and disseminations, consisting of what looks to be pyrite, honey-colored sphalerite, freibergite, galena, and minor chalcopyrite, Masivo notes that visual observations of mineralization are not a substitute for laboratory assays, and all samples will be submitted for analysis and results will be reported once received, reviewed, and verified.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will virtually present and host investor meetings at the Sidoti Small Cap Conference on Wednesday, March 18, 2026. The Company presentation is scheduled to begin at 1:45 p.m. Eastern Time. A live audio webcast of t.
Anthropic National Security Council member Josh Hodges reacted to the Trump administration's labeling of Claude during an appearance on “Mornings with Maria,” defending the technology and outlining the company's stance on safety, oversight, and secure integration with government systems. 00:00 Pentagon's AI Dilemma with Anthropic 08:01:49 Anthropic's Stance: Human Oversight & Surveillance Fears 08:04:31 LIVE Pentagon Briefing by Secretary Pete Hegseth [ASIDE] 08:09:09 AI Guardrails: Machine vs.
908 Devices Inc. (NASDAQ: MASS - Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 3,828,392 shares, a growth of 20.0% from the January 29th total of 3,189,641 shares. Currently, 13.9% of the company's stock are short sold.
908 Devices (NASDAQ: MASS) reported fourth-quarter and full-year 2025 results that management said reflected continued momentum from its strategic transformation, including stronger adoption of its handheld chemical analysis devices and improved profitability metrics. Fourth-quarter growth driven by XplorIR and new VipIR launch CEO and co-founder Kevin J. Knopp said the company generated $17.4 million in revenue
908 Devices Inc. (MASS) Q4 2025 Earnings Call Transcript
908 Devices Inc. (MASS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.32 per share a year ago.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights Revenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024 Revenue of $56.2 million for the full year.
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) (FSE: R74) ("Masivo" or the "Company") is pleased to announce that the Company's Phase I diamond drill program has begun at its Cerro Colorado Project in Sonora, Mexico. The initial phase of the program consists of approximately eight (8) diamond drill holes totaling an estimated 1,500 to 2,000 meters.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will participate in the following investor conferences. TD Cowen 46th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 4 at 9:10 a.m. Eastern Time Leerink Global Healthcare Conference, Miami, FL Fireside chat on Monday, March 9 at 1:40 p.m.
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “.
BURLINGTON, Mass.--(BUSINESS WIRE)-- #chemicalID--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces new capabilities for its handheld MX908 mass spectrometry device for trace chemical identification. These enhancements include an updated mission mode for hazardous vapor sampling and the addition of five priority drug targets, providing first responders with intelligence at the point of need for an informed, confident response. The MX908 mission mode.
Vaso (OTCMKTS:VASO - Get Free Report) and 908 Devices (NASDAQ: MASS - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations. Profitability This table compares Vaso and 908 Devices'